Table 1. The effect of in vivo Campath... | American Society of Hematology

Table 1.

The effect of in vivo Campath and conditioning therapy on circulating DC numbers before transplant

Patient age/sex	Diagnosis	Conditioning	Number of DCs (× 10⁶/L)			% Depletion after 1st dose of Campath
Patient age/sex	Diagnosis	Conditioning	Pretransplant	24 h after 1st dose of Campath	Day 0	% Depletion after 1st dose of Campath
51/M	NHL	BEAM/Campath	5.56	0.48	0	91
20/F	AML	TBI/Cy/Campath	10.38	3.97	0	61
37/M	MM	TBI/Cy/Campath	10.89	1.25	0	88
20/M	ALL	TBI/Cy/Campath	5.48	1.09	0.20	80
63/F	MM	BEAM/Campath	4.61	0.64	0	80
47/F	AML	TBI/Cy/Campath	18.48	2.08	0	88
58/F	AML	TBI/Cy/Campath	13.22	7.34	0	44
43/F	NHL	BEAM/Campath	5.34	—	0.09	—
20/M	ALL	TBI/Cy/Campath	25.87	3.90	0	85
55/M	NHL	BEAM/Campath	19.19	0.80	—	96
53/M	NHL	BEAM	6.92	—	1.42	—
29/M	NHL	TBI/Cy	23.62	—	3.00	—
49/M	NHL	BEAM	32.93	—	0	—
49/F	NHL	BEAM	8.30	—	0.26	—
26/F	NHL	BEAM	21.22	—	0.23	—
51/F	NHL	BEAM	11.45	—	0.15	—
32/M	NHL	TBI/Cy	0.54	—	0.35	—

Patient age/sex	Diagnosis	Conditioning	Number of DCs (× 10⁶/L)			% Depletion after 1st dose of Campath
Patient age/sex	Diagnosis	Conditioning	Pretransplant	24 h after 1st dose of Campath	Day 0	% Depletion after 1st dose of Campath
51/M	NHL	BEAM/Campath	5.56	0.48	0	91
20/F	AML	TBI/Cy/Campath	10.38	3.97	0	61
37/M	MM	TBI/Cy/Campath	10.89	1.25	0	88
20/M	ALL	TBI/Cy/Campath	5.48	1.09	0.20	80
63/F	MM	BEAM/Campath	4.61	0.64	0	80
47/F	AML	TBI/Cy/Campath	18.48	2.08	0	88
58/F	AML	TBI/Cy/Campath	13.22	7.34	0	44
43/F	NHL	BEAM/Campath	5.34	—	0.09	—
20/M	ALL	TBI/Cy/Campath	25.87	3.90	0	85
55/M	NHL	BEAM/Campath	19.19	0.80	—	96
53/M	NHL	BEAM	6.92	—	1.42	—
29/M	NHL	TBI/Cy	23.62	—	3.00	—
49/M	NHL	BEAM	32.93	—	0	—
49/F	NHL	BEAM	8.30	—	0.26	—
26/F	NHL	BEAM	21.22	—	0.23	—
51/F	NHL	BEAM	11.45	—	0.15	—
32/M	NHL	TBI/Cy	0.54	—	0.35	—

NHL indicates non-Hodgkin lymphoma; Cy, cyclophosphamide; AML, acute myeloid leukemia; MM, multiple myeloma.